Dabrowski et al. documented a significant reduction (p<0.0001) in the recurrence of symptomatic AF episodes in patients with symptomatic paroxysmal AF treated with spironolactone 25 mg/day compared to patients treated with enalapril or a beta-blocker. In addition, the effect of spironolactone was more prominent than that of enalapril already after 9-12 months treatment, where the effect of enalapril was less pronounced. Moreover, the addition of enalapril to spironolactone did not influence the frequency of AF recurrences.